Publications
Detailed Information
The combined use of risperidone long-acting injection and clozapine in patients with schizophrenia non-adherent to clozapine: a case series
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Se Hyun | - |
dc.contributor.author | Jung, Dong Chung | - |
dc.contributor.author | Ahn, Yong Min | - |
dc.contributor.author | Kim, Yong Sik | - |
dc.date.accessioned | 2012-07-04T07:30:44Z | - |
dc.date.available | 2012-07-04T07:30:44Z | - |
dc.date.issued | 2010-07 | - |
dc.identifier.citation | JOURNAL OF PSYCHOPHARMACOLOGY; Vol.24 7; 981-986 | ko_KR |
dc.identifier.issn | 0269-8811 | - |
dc.identifier.uri | https://hdl.handle.net/10371/78461 | - |
dc.description.abstract | Poor adherence to clozapine treatment represents an important problem in clinical practice because additional useful treatment options are unavailable. Although switching to risperidone long-acting injection (RLAI) has been recommended for those with compliance problems, this medication has been found to be less suitable for patients who previously received clozapine. Based on the suggested beneficial effects of RLAI, such as higher rates of treatment continuation and patient satisfaction, and the possible effectiveness of oral risperidone augmentation, it seems worthwhile to try RLAI augmentation for clozapine non-adherence. In this article, we present the cases of four patients with schizophrenia undergoing combined treatment with RLAI and clozapine for more than one year after multiple relapses related to clozapine non-adherence. Durations and frequencies of hospitalizations markedly declined after RLAI augmentation. Indeed, three patients receiving RLAI and clozapine for 1.2-3.5 years were never hospitalized during this period. The lengths of hospitalizations before and after augmenting with RLAI were 54.7 +/- 33.1 and 4.2 +/- 4.2 days/year, respectively. Participants also showed great improvements in social skills. These findings suggest the possible beneficial effects of RLAI augmentation in cases of clozapine non-adherence. However, controlled clinical trials are necessary to confirm whether RLAI augmentation represents a useful treatment option for patients who have not adhered to clozapine treatment. | ko_KR |
dc.description.sponsorship | This research was supported by a grant (03-PJ10-PG13-GD01-0002)
of the Korea Health 21 R&D project, Ministry for Health, Welfare and Family Affairs, Republic of Korea. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | SAGE PUBLICATIONS LTD | ko_KR |
dc.subject | antipsychotic | ko_KR |
dc.subject | augmentation | ko_KR |
dc.subject | risperidone long-acting injection | ko_KR |
dc.subject | schizophrenia | ko_KR |
dc.subject | clozapine | ko_KR |
dc.title | The combined use of risperidone long-acting injection and clozapine in patients with schizophrenia non-adherent to clozapine: a case series | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 김세현 | - |
dc.contributor.AlternativeAuthor | 정동청 | - |
dc.contributor.AlternativeAuthor | 안용민 | - |
dc.contributor.AlternativeAuthor | 김용식 | - |
dc.identifier.doi | 10.1177/0269881109348174 | - |
dc.citation.journaltitle | JOURNAL OF PSYCHOPHARMACOLOGY | - |
dc.description.citedreference | Taylor D, 2010, J PSYCHOPHARMACOL, V24, P995, DOI 10.1177/0269881109102611 | - |
dc.description.citedreference | Taylor DM, 2009, ACTA PSYCHIAT SCAND, V119, P419, DOI 10.1111/j.1600-0447.2009.01367.x | - |
dc.description.citedreference | Correll CU, 2009, SCHIZOPHRENIA BULL, V35, P443, DOI 10.1093/schbul/sbn018 | - |
dc.description.citedreference | Barbui C, 2009, SCHIZOPHRENIA BULL, V35, P458, DOI 10.1093/schbul/sbn030 | - |
dc.description.citedreference | Houthoofd SAMK, 2008, CLIN THER, V30, P1565, DOI 10.1016/j.clinthera.2008.09.014 | - |
dc.description.citedreference | Hughes DA, 2008, BRIT J CLIN PHARMACO, V65, P871, DOI 10.1111/j.1365-2125.2008.03124.x | - |
dc.description.citedreference | Chang JS, 2008, J CLIN PSYCHIAT, V69, P720 | - |
dc.description.citedreference | Morken G, 2008, BMC PSYCHIATRY, V8, DOI 10.1186/1471-244X-8-32 | - |
dc.description.citedreference | Taylor M, 2008, J PSYCHOPHARMACOL, V22, P128, DOI 10.1177/0269881107084068 | - |
dc.description.citedreference | GOREN JL, 2008, JT COMM J QUAL PATIE, V34, P571 | - |
dc.description.citedreference | Gharabawi G, 2007, J NERV MENT DIS, V195, P976, DOI 10.1097/NMD.0b013e31815c1982 | - |
dc.description.citedreference | Hamer S, 2007, BRIT J PSYCHIAT, V191, pS64, DOI 10.1192/bjp.191.50.s64 | - |
dc.description.citedreference | Tirupati S, 2007, AUST NZ J PSYCHIAT, V41, P606, DOI 10.1080/00048670701392841 | - |
dc.description.citedreference | Chetty M, 2007, CURR DRUG METAB, V8, P307 | - |
dc.description.citedreference | Paton C, 2007, J CLIN PSYCHOPHARM, V27, P198, DOI 10.1097/JCP.0b013e318036bfbb | - |
dc.description.citedreference | Chue P, 2007, CNS DRUGS, V21, P441 | - |
dc.description.citedreference | Correll CU, 2007, SCHIZOPHR RES, V89, P91, DOI 10.1016/j.schres.2006.08.017 | - |
dc.description.citedreference | Tunis SL, 2007, CURR MED RES OPIN, V23, P97, DOI 10.1185/030079907X162665 | - |
dc.description.citedreference | MARINIS TD, 2007, PHARMACOPSYCHIATRY, V40, P257 | - |
dc.description.citedreference | Taylor DM, 2006, INT J NEUROPSYCHOPH, V9, P685, DOI 10.1017/S1461145705006309 | - |
dc.description.citedreference | Lewis SW, 2006, SCHIZOPHRENIA BULL, V32, P715, DOI 10.1093/schbul/sbj067 | - |
dc.description.citedreference | McEvoy JP, 2006, AM J PSYCHIAT, V163, P600 | - |
dc.description.citedreference | Honer WG, 2006, NEW ENGL J MED, V354, P472 | - |
dc.description.citedreference | Haro JM, 2006, EUR PSYCHIAT, V21, P41, DOI 10.1016/j.eurpsy.2005.12.001 | - |
dc.description.citedreference | Lasser RA, 2005, INT J NEUROPSYCHOPH, V8, P427, DOI 10.1017/S1461145705005225 | - |
dc.description.citedreference | Kontaxakis VP, 2005, EUR PSYCHIAT, V20, P409, DOI 10.1016/j.eurpsy.2004.12.007 | - |
dc.description.citedreference | Ahn YM, 2005, INT CLIN PSYCHOPHARM, V20, P157 | - |
dc.description.citedreference | Yagcioglu AEA, 2005, J CLIN PSYCHIAT, V66, P63 | - |
dc.description.citedreference | Josiassen RC, 2005, AM J PSYCHIAT, V162, P130 | - |
dc.description.citedreference | Eerdekens M, 2004, SCHIZOPHR RES, V70, P91, DOI 10.1016/j.schres.2003.11.001 | - |
dc.description.citedreference | Kane JM, 2003, AM J PSYCHIAT, V160, P1125 | - |
dc.description.citedreference | Kane JM, 2003, J CLIN PSYCHIAT, V64, P19 | - |
dc.description.citedreference | Raaska K, 2002, EUR J CLIN PHARMACOL, V58, P587, DOI 10.1007/s00228-002-0523-9 | - |
dc.description.citedreference | Freudenreich O, 2002, ACTA PSYCHIAT SCAND, V106, P323 | - |
dc.description.citedreference | Lacro JP, 2002, J CLIN PSYCHIAT, V63, P892 | - |
dc.description.citedreference | Gaertner I, 2001, J CLIN PSYCHOPHARM, V21, P305 | - |
dc.description.citedreference | Davydov L, 2000, ANN PHARMACOTHER, V34, P662 | - |
dc.description.citedreference | Ciapparelli A, 2000, J CLIN PSYCHIAT, V61, P329 | - |
dc.description.citedreference | Conley RR, 1999, AM J PSYCHIAT, V156, P863 | - |
dc.description.citedreference | Pollack S, 1998, PSYCHOPHARMACOL BULL, V34, P89 | - |
dc.description.citedreference | Shiloh R, 1997, BRIT J PSYCHIAT, V171, P569 | - |
dc.description.citedreference | Schooler NR, 1997, ARCH GEN PSYCHIAT, V54, P453 | - |
dc.description.citedreference | KOREEN AR, 1995, AM J PSYCHIAT, V152, P1690 | - |
dc.description.citedreference | TYSON SC, 1995, AM J PSYCHIAT, V152, P1401 | - |
dc.description.citedreference | MARINKOVIC D, 1994, PROG NEURO-PSYCHOPH, V18, P537 | - |
dc.description.citedreference | BURKE M, 1993, AM J PSYCHIAT, V150, P1900 | - |
dc.description.tc | 0 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.